Lapatinib (base)
EGFR and HER2 inhibitor / Potent inhibitor of EGFR kinase (Ki=3 nM), Erb-2 kinase (Ki=13 nM) Erb-4 kinase (Ki=347 nM)1. Clinically useful agent for treatment of breast cancer2-3. Cell permeable
Biochemicals & reagents
231277-92-2
GW-572016
1) Wood et al. (2004), A unique structure for epidermal growth fsctor receptor bound to GW572016 (Lapatinib): relationships among protein conformation, inhibitor off-rate, and receptor activity in tumor cells; Cancer Res., 64 6652 2) Burris et al. (2004), Dual kinase inhibition in the treatment of breast cancer: initial experience with the EGFR/ErbB-2 inhibitor lapatinib; Oncologist, 9 10 3) Chu et al. (2005), The dual ErbB1/ErbB2 inhibitor, lapatinib (GW572016) cooperates with tamoxifen to inhibit both cell proliferation- and estrogen-dependent gene expression in antiestrogen-resistant breast cancer; Cancer Res., 65 18
-20°C
TARGET: Kinase -- PATHWAY: Estrogen -- DISEASE AREA: Cancer